Entero Healthcar
Entero Healthcar Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Targeting over 30% revenue growth in FY ‘26, similar or better than FY ‘25’s 30% growth. - FY ‘25 growth comprised 16% organic growth and remaining from acquisitions; organic growth is expected to continue at 1.5x to 2x the Indian Pharmaceutical Market (IPM) growth rate. - IPM assumed growth is ~8%; therefore, organic growth is anticipated around 15%-16%. - Full-year impact of last year’s acquisitions expected to add approximately Rs. FY ‘26 revenue growth target: >30%, continuing the momentum from FY ‘25 (30% growth).
From Entero Healthcar's Q4 FY25 earnings-call transcript · updated 26 Aug 2026.
Revenue & Sales Performance
- Targeting over 30% revenue growth in FY ‘26, similar or better than FY ‘25’s 30% growth.
- FY ‘25 growth comprised 16% organic growth and remaining from acquisitions; organic growth is expected to continue at 1.5x to 2x the Indian Pharmaceutical Market (IPM) growth rate.
- IPM assumed growth is ~8%; therefore, organic growth is anticipated around 15%-16%.
- Full-year impact of last year’s acquisitions expected to add approximately Rs. 500 crores.
- New acquisitions in FY ‘26 expected to add over Rs. 400 crores in annualized revenues.
- Long-term plan includes doubling down on organic expansion via new pharmacies, hospitals, and increased wallet share.
- Growth strategy balanced between organic growth and margin-accretive inorganic acquisitions.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Entero Healthcar said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- No explicit mention of current or future capex or capital investment plans in the transcript.
- Focus remains on inorganic growth through acquisitions; recently completed 10 acquisitions and pipeline continues.
- Investments largely in acquisitions to expand geographic footprint, product portfolio, and capabilities.
- Emphasis on operational efficiencies, technology-led solutions, and building a digitally integrated healthcare distribution platform.
- Working capital improvements and margin expansion targeted to drive positive operating cash flows from FY ‘26.
2 more points management made on capital expenditure plans
Top-ranked in Retailing
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Entero Healthcar said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The transcript does not explicitly mention a current or expected order book or pending orders.
- Discussion focuses on acquisitions, integration timelines, and revenue growth guidance.
- Prabhat Agarwal mentions a timeline of about two to two and a half months to close remaining acquisitions, aiming to complete sooner.
- Total consideration for acquisitions is confidential; multiples are guided between 5x to 7x EV/EBITDA.
2 more points management made on order book & pipeline
Entero Healthcar — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.9K Cr, net profit ₹45 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Entero Healthcar's management said in earlier quarters
Others in Retailing this season
- Trent (Q4 FY25)
GST): ₹17,624 crore (Page 6) . Key concall takeaways from Trent Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Baazar Style (Q4 FY25)
Store additions planned around 40 to 50 stores in FY ’26, with 20% to 25% increase in store count. Key concall takeaways from Baazar Style Retail Ltd's Q4 FY25…
- V2 Retail (Q4 FY25)
Volume growth remains strong, with 43% growth in FY25, supported by increased store count and product acceptance. Key concall takeaways from V2 Retail's Q4…
- FSN E-Commerce (Q4 FY25)
Nykaa’s overall GMV grew 27% YoY in Q4 and 25% for the full year FY25, with net revenue growth at 24% YoY for the full year. Key concall takeaways from FSN…
Frequently Asked Questions
What were Entero Healthcar Q4 FY25 results?
Targeting over 30% revenue growth in FY ‘26, similar or better than FY ‘25’s 30% growth. - FY ‘25 growth comprised 16% organic growth and remaining from acquisitions; organic growth is expected to continue at 1.5x to 2x the Indian Pharmaceutical Market (IPM) growth rate. - IPM assumed growth is ~8%; therefore, organic growth is anticipated around 15%-16%. - Full-year impact of last year’s acquisitions expected to add approximately Rs. FY ‘26 revenue growth target: >30%, continuing the momentum from FY ‘25 (30% growth).
What is Entero Healthcar share price analysis?
Entero Healthcar currently shows a neutral. The stock trades at a P/E of 48.0 with a market cap of ₹6,196 Cr. Investors should review the full earnings analysis for detailed insights.
Is Entero Healthcar planning capital expenditure?
No explicit mention of current or future capex or capital investment plans in the transcript.
Keep Entero Healthcar on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.